About this trial
Disseminated Intravascular Coagulation is a severe complication of septic shock, associated with high mortality, whose diagnosis relies on complex scores that are rarely used in practice. Preliminary studies have shown that increased neutrophil fluorescence is associated with Disseminated Intravascular Coagulation and could reflect NETosis, a key mechanism of immunothrombosis. This study aims to validate neutrophil fluorescence measured on the SthemA 801 analyzer, alone or integrated into an artificial intelligence model, as an early, reliable, and routinely usable biomarker for the diagnosis of septic Disseminated Intravascular Coagulation.
Eligibility criteria
Qualifiers
Male or female ≥ 18 years old
Patient admitted to intensive care for septic shock
Patient affiliated with a social security scheme or having rights
No objection from the patient or a relative in case the patient is not able to express consent, or inclusion under emergency procedure in case the patient is not able to express their opinion and no relative of the patient is reachable.
Disqualifiers
Moribund patient on the day of inclusion
Child-Pugh C cirrhosis
Neutropenia (<500 mm3)
Patient under legal protection
Trial design
Treatments tested in this trial
- Not listed